MiR-582-3p regulates endothelial cell function in lower extremity deep vein thrombosis by targeting TFRC.

MicroRNAs (miRNAs) have been widely explored in the study and management of lower extremity deep vein thrombosis (LEDVT). However, the function and mechanism of miR-582-3p in LEDVT remain unclear. The study aimed to explore the expression and regulatory functions of miR-582-3p in LEDVT and Human Umbilical Vein Endothelial Cells (HUVECs). Serum samples from 118 LEDVT patients and 82 healthy controls were collected. RT-qPCR was used to detect the expression levels of miR-582-3p and TFRC in serum and cells. The AUC and logistic analysis were used for the diagnosis and risk prediction of LEDVT. ox-LDL treated HUVECs were used to construct injury cell models. The CCK8, flow cytometry, and ELISA were employed to analyze cell function. Dual-luciferase reporter assays and rescue experiments verified the regulatory relationship between miR-582-3p and TFRC. MiR-582-3p was significantly downregulated in LEDVT patients and in ox-LDL-HUVECs. It was negatively correlated with the levels of D-dimer and TAT III. Additionally, for miR-582-3p, the AUC was 0.870, and it was an independent protective factor. MiR-582-3p mimics promoted the proliferation of ox-LDL-HUVECs, inhibited their apoptosis, and reduced the levels of inflammatory factors (TNF-α, IL-1β, IL-6) and coagulation factors (FXⅢ, TF, PAF). Additionally, miR-582-3p directly targeted TFRC, and overexpression of TFRC reversed the protective effect of miR-582-3p against ox-LDL-induced cellular damage. MiR-582-3p is a potential diagnostic biomarker and independent protective factor for LEDVT. MiR-582-3p regulates endothelial cell function by targeting TFRC, suggesting its potential as a therapeutic target for LEDVT.